Sellas Life Sciences Narrows FY25 Net Loss Amid Promising Trials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SLS?
Source: stocktwits
- Financial Improvement: Sellas Life Sciences reported a narrowed net loss of $26.9 million for FY25, down from $30.9 million in FY24, with R&D expenses decreasing to $16 million, indicating effective cost management that enhances investor confidence.
- Clinical Trial Progress: The Phase 3 Regal AML trial is nearing final analysis with 72 out of the required 80 survival events recorded, which is expected to drive the upcoming topline data release, potentially leading to positive stock price movements.
- New Drug Development: SLS009 is advancing into first-line AML trials, supported by prior data showing a 46% response rate, with upcoming AACR preclinical results set to further validate its efficacy, thereby strengthening the company's competitive position in AML treatment.
- Strong Cash Position: Sellas ended FY25 with $71.8 million in cash and cash equivalents and received an additional $42.6 million from warrant exercises in Q1 2026, demonstrating financial stability that supports future R&D and market expansion efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLS
Wall Street analysts forecast SLS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.950
Low
7.00
Averages
7.25
High
7.50
Current: 4.950
Low
7.00
Averages
7.25
High
7.50
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SELLAS Life Sciences FY 2025 Earnings Beat Expectations
- Earnings Performance: SELLAS Life Sciences reported a FY 2025 GAAP EPS of -$0.25, beating expectations by $0.01, indicating some improvement in financial management despite still being in a loss position.
- Cash Position: As of December 31, 2025, the company had approximately $71.8 million in cash and cash equivalents, ensuring liquidity and financial stability for future operations, which can support R&D and market expansion.
- Funding Progress: Subsequent to December 31, 2025, the company received an additional $42.6 million from the exercise of previously outstanding warrants, providing financial support for upcoming project developments and clinical trials, thereby boosting market confidence.
- Potential Catalyst: The upcoming REGAL study results are expected to be a significant catalyst for SELLAS Life Sciences; if the results are positive, they could substantially enhance the company's stock price and market recognition, driving future growth.
See More
Sellas Life Sciences Narrows FY25 Net Loss Amid Promising Trials
- Financial Improvement: Sellas Life Sciences reported a narrowed net loss of $26.9 million for FY25, down from $30.9 million in FY24, with R&D expenses decreasing to $16 million, indicating effective cost management that enhances investor confidence.
- Clinical Trial Progress: The Phase 3 Regal AML trial is nearing final analysis with 72 out of the required 80 survival events recorded, which is expected to drive the upcoming topline data release, potentially leading to positive stock price movements.
- New Drug Development: SLS009 is advancing into first-line AML trials, supported by prior data showing a 46% response rate, with upcoming AACR preclinical results set to further validate its efficacy, thereby strengthening the company's competitive position in AML treatment.
- Strong Cash Position: Sellas ended FY25 with $71.8 million in cash and cash equivalents and received an additional $42.6 million from warrant exercises in Q1 2026, demonstrating financial stability that supports future R&D and market expansion efforts.
See More
Sellas Life Sciences Highlights Promising Data for AML Drug SLS009 Ahead of AACR 2026
- Clinical Data Highlight: Sellas Life Sciences is set to present compelling preclinical data for its acute myeloid leukemia (AML) drug SLS009 at the upcoming AACR 2026 conference, with CEO Stergiou emphasizing its activity in high-risk mutations like ASXL1 and TP53, which could significantly enhance the company's market prospects.
- Trial Progress: The company recently enrolled its first patient in a Phase 2 trial targeting newly diagnosed AML patients, aiming to recruit around 80 individuals unlikely to benefit from standard therapies, which will further advance the clinical application of SLS009.
- Efficacy Improvement: Early lab data indicate that SLS009 promotes leukemia cell self-destruction by blocking survival signals, and its potency improves significantly with repeated dosing, suggesting strong potential in treating hard-to-treat AML cases.
- Positive Market Reaction: Following the announcement of new data, SLS shares jumped nearly 6% in Wednesday trading, despite a nearly 6% decline the previous day, indicating a positive investor response that may drive future investment interest.
See More
SELLAS Initiates Phase 2 Trial for SLS009 in AML
- Trial Launch: SELLAS Life Sciences announced on Thursday that it has enrolled its first patient in a Phase 2 trial for SLS009 (tambiciclib), a selective CDK9 inhibitor designed for patients with acute myeloid leukemia (AML), indicating the company's proactive advancement in cancer treatment.
- Clear Trial Objectives: The trial aims to assess the efficacy of SLS009 in first-line AML treatment, planning to enroll approximately 80 patients across two high-need cohorts, demonstrating SELLAS's focus on precision medicine to meet clinical demands.
- Strategic Positioning: CEO Angelos Stergiou stated that by targeting molecularly defined subgroups and early non-responders, the trial aims to address critical needs in frontline AML treatment and lay the groundwork for potential registrational development of SLS009, reflecting the company's confidence in future market opportunities.
- Positive Market Reaction: Following this announcement, SELLAS Life Sciences stock traded over 1% higher in Thursday's premarket, reflecting investor optimism regarding the company's clinical progress, which could drive future financing and partnership opportunities.
See More
Sellas' Immunotherapy Trial Approaches Key Milestone
- Clinical Trial Progress: Sellas' Phase 3 Regal trial is testing the immunotherapy Galinpepimut-S (GPS) as a maintenance treatment for acute myeloid leukemia (AML) patients, with only eight more events needed to trigger the final analysis, indicating significant progress in the clinical study.
- Stock Price Surge: Shares of Sellas Life Sciences Group Inc. (SLS) rallied nearly 8% on Monday to close at $5.96, reaching a four-year high, reflecting investor optimism ahead of the anticipated clinical data release, despite some analysts expressing bearish views on the drug's efficacy.
- Investor Sentiment Shift: Over the past 24 hours, SLS saw a 580% surge in message volume on Stocktwits, with sentiment shifting from 'bullish' to 'extremely bullish', highlighting the market's heightened focus on the upcoming trial results.
- CEO Endorses Strategy: Sellas CEO Angelos Stergiou stated that GPS will target leukemia regardless of genetic mutations, aiming to activate multiple types of T cells to attack leukemic stem cells, further bolstering market confidence in the therapy.
See More
Wall Street Rebounds Amid Oil Price Volatility
- Semiconductor Stocks Lead Gains: Semiconductor stocks such as Broadcom, Micron, AMD, and Nvidia posted strong gains during Wall Street's rebound, indicating a recovery in investor confidence towards tech stocks amid volatile market conditions.
- Oil Price Volatility: Oil prices experienced dramatic swings, with West Texas Intermediate crude briefly surging to $119 per barrel after President Trump suggested the Iran conflict might be nearing an end, before retreating to the low $80s, highlighting the significant impact of geopolitical events on oil markets.
- Shifts in Market Sentiment: Despite major indexes rebounding sharply in the previous session, Nasdaq 100 and S&P 500 futures traded down about 0.4% late Monday, reflecting investor caution ahead of key economic data and earnings reports.
- Investor Focus on Upcoming Data: The market is closely watching the NFIB Small Business Optimism Index and existing home sales data, while upcoming earnings reports from Oracle and Adobe are expected to serve as important catalysts for market movement.
See More
SELLAS Life Sciences FY 2025 Earnings Beat Expectations
- Earnings Performance: SELLAS Life Sciences reported a FY 2025 GAAP EPS of -$0.25, beating expectations by $0.01, indicating some improvement in financial management despite still being in a loss position.
- Cash Position: As of December 31, 2025, the company had approximately $71.8 million in cash and cash equivalents, ensuring liquidity and financial stability for future operations, which can support R&D and market expansion.
- Funding Progress: Subsequent to December 31, 2025, the company received an additional $42.6 million from the exercise of previously outstanding warrants, providing financial support for upcoming project developments and clinical trials, thereby boosting market confidence.
- Potential Catalyst: The upcoming REGAL study results are expected to be a significant catalyst for SELLAS Life Sciences; if the results are positive, they could substantially enhance the company's stock price and market recognition, driving future growth.
See More
Sellas Life Sciences Narrows FY25 Net Loss Amid Promising Trials
- Financial Improvement: Sellas Life Sciences reported a narrowed net loss of $26.9 million for FY25, down from $30.9 million in FY24, with R&D expenses decreasing to $16 million, indicating effective cost management that enhances investor confidence.
- Clinical Trial Progress: The Phase 3 Regal AML trial is nearing final analysis with 72 out of the required 80 survival events recorded, which is expected to drive the upcoming topline data release, potentially leading to positive stock price movements.
- New Drug Development: SLS009 is advancing into first-line AML trials, supported by prior data showing a 46% response rate, with upcoming AACR preclinical results set to further validate its efficacy, thereby strengthening the company's competitive position in AML treatment.
- Strong Cash Position: Sellas ended FY25 with $71.8 million in cash and cash equivalents and received an additional $42.6 million from warrant exercises in Q1 2026, demonstrating financial stability that supports future R&D and market expansion efforts.
See More
Sellas Life Sciences Highlights Promising Data for AML Drug SLS009 Ahead of AACR 2026
- Clinical Data Highlight: Sellas Life Sciences is set to present compelling preclinical data for its acute myeloid leukemia (AML) drug SLS009 at the upcoming AACR 2026 conference, with CEO Stergiou emphasizing its activity in high-risk mutations like ASXL1 and TP53, which could significantly enhance the company's market prospects.
- Trial Progress: The company recently enrolled its first patient in a Phase 2 trial targeting newly diagnosed AML patients, aiming to recruit around 80 individuals unlikely to benefit from standard therapies, which will further advance the clinical application of SLS009.
- Efficacy Improvement: Early lab data indicate that SLS009 promotes leukemia cell self-destruction by blocking survival signals, and its potency improves significantly with repeated dosing, suggesting strong potential in treating hard-to-treat AML cases.
- Positive Market Reaction: Following the announcement of new data, SLS shares jumped nearly 6% in Wednesday trading, despite a nearly 6% decline the previous day, indicating a positive investor response that may drive future investment interest.
See More
SELLAS Initiates Phase 2 Trial for SLS009 in AML
- Trial Launch: SELLAS Life Sciences announced on Thursday that it has enrolled its first patient in a Phase 2 trial for SLS009 (tambiciclib), a selective CDK9 inhibitor designed for patients with acute myeloid leukemia (AML), indicating the company's proactive advancement in cancer treatment.
- Clear Trial Objectives: The trial aims to assess the efficacy of SLS009 in first-line AML treatment, planning to enroll approximately 80 patients across two high-need cohorts, demonstrating SELLAS's focus on precision medicine to meet clinical demands.
- Strategic Positioning: CEO Angelos Stergiou stated that by targeting molecularly defined subgroups and early non-responders, the trial aims to address critical needs in frontline AML treatment and lay the groundwork for potential registrational development of SLS009, reflecting the company's confidence in future market opportunities.
- Positive Market Reaction: Following this announcement, SELLAS Life Sciences stock traded over 1% higher in Thursday's premarket, reflecting investor optimism regarding the company's clinical progress, which could drive future financing and partnership opportunities.
See More
Sellas' Immunotherapy Trial Approaches Key Milestone
- Clinical Trial Progress: Sellas' Phase 3 Regal trial is testing the immunotherapy Galinpepimut-S (GPS) as a maintenance treatment for acute myeloid leukemia (AML) patients, with only eight more events needed to trigger the final analysis, indicating significant progress in the clinical study.
- Stock Price Surge: Shares of Sellas Life Sciences Group Inc. (SLS) rallied nearly 8% on Monday to close at $5.96, reaching a four-year high, reflecting investor optimism ahead of the anticipated clinical data release, despite some analysts expressing bearish views on the drug's efficacy.
- Investor Sentiment Shift: Over the past 24 hours, SLS saw a 580% surge in message volume on Stocktwits, with sentiment shifting from 'bullish' to 'extremely bullish', highlighting the market's heightened focus on the upcoming trial results.
- CEO Endorses Strategy: Sellas CEO Angelos Stergiou stated that GPS will target leukemia regardless of genetic mutations, aiming to activate multiple types of T cells to attack leukemic stem cells, further bolstering market confidence in the therapy.
See More
Wall Street Rebounds Amid Oil Price Volatility
- Semiconductor Stocks Lead Gains: Semiconductor stocks such as Broadcom, Micron, AMD, and Nvidia posted strong gains during Wall Street's rebound, indicating a recovery in investor confidence towards tech stocks amid volatile market conditions.
- Oil Price Volatility: Oil prices experienced dramatic swings, with West Texas Intermediate crude briefly surging to $119 per barrel after President Trump suggested the Iran conflict might be nearing an end, before retreating to the low $80s, highlighting the significant impact of geopolitical events on oil markets.
- Shifts in Market Sentiment: Despite major indexes rebounding sharply in the previous session, Nasdaq 100 and S&P 500 futures traded down about 0.4% late Monday, reflecting investor caution ahead of key economic data and earnings reports.
- Investor Focus on Upcoming Data: The market is closely watching the NFIB Small Business Optimism Index and existing home sales data, while upcoming earnings reports from Oracle and Adobe are expected to serve as important catalysts for market movement.
See More
